Ankrd36bp1: A Non-coding RNA Molecule as A Potential Drug Target

Target Name: ANKRD36BP1

NCBI ID: G84832

ANKRD36BP1

Other Name(s): ANKRD26L1 | ANKRD36BL1 | ankyrin repeat domain 36B pseudogene 1 | Ankyrin repeat domain 36B pseudogene 1

Ankrd36bp1: A Non-coding RNA Molecule as A Potential Drug Target

ANKRD36BP1 (ANKRD26L1) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the T-cell receptor (TCR), which is a critical molecule involved in immune response and cell differentiation. The expression level of ANKRD36BP1 changes in various cancers and plays an important role in tumor occurrence and development.

ANKRD36BP1 is an RNA molecule encoded by a nucleotide sequence and belongs to the HIPK3 family. It was originally discovered on human chromosomes and plays an important role in a variety of cancers. The expression level of ANKRD36BP1 changes in various cancers and plays an important role in tumor occurrence and development.

The expression level of ANKRD36BP1 changes in various cancers and plays an important role in tumor occurrence and development. Studies have shown that the expression level of ANKRD36BP1 is positively correlated with the prognosis of various cancers, including lung cancer, breast cancer, gastric cancer, etc. In addition, the expression level of ANKRD36BP1 is also related to tumor invasion and metastasis.

The expression level of ANKRD36BP1 changes in various cancers and plays an important role in tumor occurrence and development. Studies have shown that the expression level of ANKRD36BP1 is positively correlated with the prognosis of various cancers, including lung cancer, breast cancer, gastric cancer, etc. In addition, the expression level of ANKRD36BP1 is also related to tumor invasion and metastasis.

ANKRD36BP1 is also closely related to a series of biological processes, including cell cycle, cell proliferation, apoptosis, etc. Research shows that ANKRD36BP1 plays an important role in the cell cycle and participates in the S phase of the cell cycle. In addition, ANKRD36BP1 is also closely related to apoptosis and participates in the apoptosis signaling pathway during apoptosis.

ANKRD36BP1 is also closely related to a series of biological processes, including cell cycle, cell proliferation, apoptosis, etc. Research shows that ANKRD36BP1 plays an important role in the cell cycle and participates in the S phase of the cell cycle. In addition, ANKRD36BP1 is also closely related to apoptosis and participates in the apoptosis signaling pathway during apoptosis.

In addition, ANKRD36BP1 also interacts with a variety of proteins, including FAK, PI3K, AKT, etc. Studies have shown that ANKRD36BP1 regulates a variety of biological processes through these protein pathways, including cell proliferation, apoptosis, cell cycle, etc.

Based on the above analysis, ANKRD36BP1, as a non-coding RNA molecule, has a variety of biological functions, including regulating cell cycle, participating in apoptosis, regulating cell proliferation, etc. These functions play important roles in tumorigenesis and progression, so ANKRD36BP1 is a potential drug target. In the future, researchers will continue to further study the mechanism of ANKRD36BP1 in tumor occurrence and development, explore its potential as a drug target and develop new treatment methods.

Protein Name: Ankyrin Repeat Domain 36B Pseudogene 1

The "ANKRD36BP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKRD36BP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets